ClinicalTrials.gg
CompletedNCT02275780DRIVE-FORWARDUpdated Oct 1, 2024Results posted

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

A Phase 3 interventional study of Doravirine and Darunavir in HIV-1, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
769
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To establish a new treatment option for treatment-naïve participants with HIV-1, the efficacy and safety of doravirine will be determined relative to a protease inhibitor (PI). Participants will receive double-blind treatment during the 96-week Base Study. Eligible participants in either of the Base Study groups will continue to receive the doravirine-containing regimen open label for an additional 96 weeks in the Study Extension 1. Eligible participants who are deriving benefit will continue in Study Extension 2 to receive the doravirine-containing regimen open label until doravirine becomes locally available or for an additional 96 weeks, whichever comes first. The primary hypothesis is that doravirine 100 mg once a day (q.d.) is non-inferior to darunavir/ritonavir (800 mg/100 mg) q.d., each in combination with TRUVADA™ or EPZICOM™/KIVEXA™, as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) \<50 copies/mL at Week 48. If non-inferiority is established, then the superiority of doravirine 100 mg q.d. compared to darunavir/ ritonavir (800 mg/100 mg) q.d. will be assessed.

Read the detailed description

Participants in Australia, Russia, and South Africa who are deriving benefit from MK-1439A are also eligible to continue receiving study drug during Study Extension 3, which will last for 2 years or until drug is available locally, whichever comes first.

02

Conditions studied

  • HIV-1
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is -1 positive and has HIV treatment indicated based on physician assessment.
  • Has received no (0 days of) antiretroviral therapy (ART), including antiretroviral agents.
  • Is considered clinically stable with no signs or symptoms of active infection for at least 2 weeks prior to the start of treatment.
  • Female is highly unlikely to become pregnant, or male is highly unlikely to impregnate a partner because they are not of , or agree to practice abstinence or use acceptable for up to 14 days after the last dose of study drug.
  • Eligibility for the Study Extension 1 at the Week 96 visit: 1) completed the Week 96 visit, 2) derived benefit from participation through Week 96 in the opinion of the investigator, 3) is a clinically-appropriate candidate for an additional 96 weeks of treatment with the Study Extension regimen.
  • Eligibility for the Study Extension 2 at the Week 192 visit: 1) completed the Week 192 visit, 2) derived benefit from participation through Week 192 in the opinion of the investigator, 3) is a clinically-appropriate candidate for 96 weeks of treatment with the Study Extension regimen.

Exclusion criteria

Exclusion Criteria:

  • Uses or has had a recent history of using recreational or illicit drugs.
  • Has been treated for a viral infection other than -1, such as , with an agent that is active against HIV-1.
  • Has documented or known resistance to study drugs including doravirine, darunavir, ritonavir, emtricitabine, tenofovir, abacavir and/or lamivudine.
  • Has participated in a study with an compound/device within the prior month, or anticipates doing so during this study.
  • Has used systemic therapy or immune modulators within the prior 30 days, or anticipates doing so during this study.
  • Has significant or other to any of the components of the study drugs.
  • Has a current (active) diagnosis of acute hepatitis due to any cause.
  • Is pregnant, breastfeeding or expecting to conceive at any time during the study.
  • Female who expects to donate eggs, or male who expects to donate sperm at any time during the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
769 participants (actual)

Study arms

  • Experimental
    Doravirine 100 mg

    Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for 96 weeks in the Base Study. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o. q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the Doravirine regimen in Study Extension 2 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first. Eligible participants may continue to receive the Doravirine regimen in Study Extension 3 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.

    Drug: Doravirine · Drug: TRUVADA™ or EPZICOM™/KIVEXA™

  • Active comparator
    Darunavir 800 mg and Ritonavir 100 mg

    Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o. q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o. q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for an additional 96 weeks. Eligible participants may continue to receive the Doravirine regimen in Study Extension 2 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first. Eligible participants may continue to receive the Doravirine regimen in Study Extension 3 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.

    Drug: Doravirine · Drug: Darunavir · Drug: Ritonavir · Drug: TRUVADA™ or EPZICOM™/KIVEXA™

Interventions

  • Doravirine 100 mg tablet administered p.o. q.d.

  • Darunavir 800 mg tablet administered p.o. q.d.

  • Ritonavir 100 mg tablet administered p.o. q.d.

  • DrugTRUVADA™ or EPZICOM™/KIVEXA™

    The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o. q.d.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 48

    The percentage of participants in each arm achieving HIV-1 RNA levels \<50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 96

    The percentage of participants in each arm achieving HIV-1 RNA levels \<50 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.

    Time frame: Week 96

  2. Change From Baseline in Mean CD4+ T-cell Count at Week 48

    CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.

    Time frame: Baseline and Week 48

  3. Change From Baseline in Mean CD4+ T-cell Count at Week 96

    CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.

    Time frame: Baseline and Week 96

  4. Mean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48

    Serum LDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The Last Observation Carry Forward (LOCF) approach was applied for missing data or data collected after modifying lipid-lowering therapy.

    Time frame: Baseline and Week 48

  5. Mean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48

    Serum non-HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.

    Time frame: Baseline and Week 48

  6. Mean Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 48

    Serum HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.

    Time frame: Baseline and Week 48

  7. Mean Change From Baseline in Fasting Total Cholesterol at Week 48

    Serum total cholesterol was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.

    Time frame: Baseline and Week 48

  8. Mean Change From Baseline in Fasting Triglyceride at Week 48

    Serum triglyceride was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.

    Time frame: Baseline and Week 48

  9. Percentage of Participants With Any Adverse Event

    An adverse event (AE) is defined as any untoward medical occurrence in a study participant and which does not necessarily have to have a causal relationship to treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the study treatment or protocol-specified procedure, whether or not considered related to study treatment or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study treatment is also an AE. The percentage of participants with any AE was assessed.

    Time frame: Up to 98 weeks

  10. Percentage of Participants With Any Serious Adverse Event

    A serious adverse event is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants with any SAE was assessed.

    Time frame: Up to 98 weeks

  11. Percentage of Participants With Any Drug-related Adverse Event

    The investigator was to determine if an AE had a reasonable possibility of a relationship to the study drug. The percentage of participants with any drug-related AE was assessed.

    Time frame: Up to 98 weeks

  12. Percentage of Participants With Any Drug-related Serious Adverse Event

    The percentage of participants with any drug-related SAE was assessed.

    Time frame: Up to 98 weeks

  13. Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event

    The percentage of participants who discontinued study treatment due to an AE was assessed.

    Time frame: Up to 96 weeks

  14. Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 48

    The percentage of participants in each arm achieving HIV-1 RNA levels \<40 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.

    Time frame: Week 48

  15. Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 96

    The percentage of participants in each arm achieving HIV-1 RNA levels \<40 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.

    Time frame: Week 96

07

Results

Posted Oct 23, 2018

Participant flow

Base Study: 96 Weeks
Participant flow — Base Study: 96 Weeks
MilestoneDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg
Started385384
Treated383383
Completed292273
Not completed93111
Withdrew: Adverse event614
Withdrew: Death31
Withdrew: Lack of efficacy2132
Withdrew: Lost to follow-up2824
Withdrew: Protocol violation16
Withdrew: Withdrawal by subject1922
Withdrew: Noncompliance with drug96
Withdrew: Physician decision24
Withdrew: Pregnancy21
Withdrew: Randomized not treated21
Study Extension 1: Week 96 to Week 192
Participant flow — Study Extension 1: Week 96 to Week 192
MilestoneDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg
Started259233
Completed210190
Not completed4943
Withdrew: Adverse event61
Withdrew: Availability of study medication locally20
Withdrew: Lack of efficacy811
Withdrew: Lost to follow-up87
Withdrew: Non-compliance with study drug12
Withdrew: Physician decision37
Withdrew: Pregnancy21
Withdrew: Withdrawal by subject1914
Study Extension 2: Week 192 to Week 288
Participant flow — Study Extension 2: Week 192 to Week 288
MilestoneDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg
Started148129
Completed10191
Not completed4738
Withdrew: Adverse event01
Withdrew: Availability of study medication locally3829
Withdrew: Lack of efficacy23
Withdrew: Lost to follow-up01
Withdrew: Non-compliance with study drug20
Withdrew: Physician decision11
Withdrew: Withdrawal by subject43
Study Extension 3: Week 288 to Week 384
Participant flow — Study Extension 3: Week 288 to Week 384
MilestoneDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg
Started5036
Completed3623
Not completed1413
Withdrew: Availability of study medication locally66
Withdrew: Death01
Withdrew: Lost to follow-up13
Withdrew: Non-compliance with study drug11
Withdrew: Physician decision10
Withdrew: Withdrawal by subject52

Outcome measures

PrimaryPercentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 48

The percentage of participants in each arm achieving HIV-1 RNA levels \<50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 48
Percentage of participantsDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 4883.879.9
Statistical analysis
  • Doravirine 100 mg vs Daurunavir 800 mg + Ritonavir 100 mg · Treatment difference: 3.913 · 95% CI -1.590 to 9.415Stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum.
SecondaryPercentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 96

The percentage of participants in each arm achieving HIV-1 RNA levels \<50 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 96
Percentage of participantsDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 9673.166.0
Statistical analysis
  • Doravirine 100 mg vs Daurunavir 800 mg + Ritonavir 100 mg · Treatment difference: 7.082 · 95% CI 0.508 to 13.656Stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum.
SecondaryChange From Baseline in Mean CD4+ T-cell Count at Week 48

CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.

Time frame:
Baseline and Week 48
Reported as:
Mean · Cells/mm^3
Change From Baseline in Mean CD4+ T-cell Count at Week 48
Cells/mm^3Doravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Change From Baseline in Mean CD4+ T-cell Count at Week 48192.7 (171.5 to 213.9)185.6 (167.5 to 203.6)
Statistical analysis
  • Doravirine 100 mg vs Daurunavir 800 mg + Ritonavir 100 mg · Mean treatment difference: 7.1 · 95% CI -20.8 to 35.0Stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum.
SecondaryChange From Baseline in Mean CD4+ T-cell Count at Week 96

CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.

Time frame:
Baseline and Week 96
Reported as:
Mean · Cells/mm^3
Change From Baseline in Mean CD4+ T-cell Count at Week 96
Cells/mm^3Doravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Change From Baseline in Mean CD4+ T-cell Count at Week 96224.1 (200.8 to 247.4)206.7 (184.9 to 228.5)
Statistical analysis
  • Doravirine 100 mg vs Daurunavir 800 mg + Ritonavir 100 mg · Mean treatment difference: 17.4 · 95% CI -14.5 to 49.3Stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum.
SecondaryMean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48

Serum LDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The Last Observation Carry Forward (LOCF) approach was applied for missing data or data collected after modifying lipid-lowering therapy.

Time frame:
Baseline and Week 48
Reported as:
Mean · mg/dL
Mean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48
mg/dLDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Baseline91.10 ± 28.6191.76 ± 30.36
Change from Baseline-4.51 ± 20.649.92 ± 27.31
Statistical analysis
  • Doravirine 100 mg vs Daurunavir 800 mg + Ritonavir 100 mg · ANCOVA · p = <0.0001 · Treatment difference (mg/dl): -14.61 · 95% CI -18.15 to -11.06Terms for Baseline lipid level and treatment group
SecondaryMean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48

Serum non-HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.

Time frame:
Baseline and Week 48
Reported as:
Mean · mg/dL
Mean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48
mg/dLDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Baseline113.34 ± 34.25114.44 ± 35.01
Change from Baseline-5.30 ± 23.2813.75 ± 31.08
Statistical analysis
  • Doravirine 100 mg vs Daurunavir 800 mg + Ritonavir 100 mg · ANCOVA · p = <0.0001 · Treatment difference (mg/dl): -19.34 · 95% CI -23.33 to -15.35Terms for Baseline lipid level and treatment group
SecondaryMean Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 48

Serum HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.

Time frame:
Baseline and Week 48
Reported as:
Mean · mg/dL
Mean Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 48
mg/dLDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Baseline43.58 ± 12.9943.27 ± 13.96
Change from Baseline3.94 ± 10.664.15 ± 11.01
SecondaryMean Change From Baseline in Fasting Total Cholesterol at Week 48

Serum total cholesterol was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.

Time frame:
Baseline and Week 48
Reported as:
Mean · mg/dL
Mean Change From Baseline in Fasting Total Cholesterol at Week 48
mg/dLDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg
Baseline156.92 ± 35.82157.71 ± 37.34
Change from Baseline-1.37 ± 25.4717.90 ± 33.95
SecondaryMean Change From Baseline in Fasting Triglyceride at Week 48

Serum triglyceride was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.

Time frame:
Baseline and Week 48
Reported as:
Mean · mg/dL
Mean Change From Baseline in Fasting Triglyceride at Week 48
mg/dLDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Baseline111.16 ± 75.31117.02 ± 97.30
Change from Baseline-3.14 ± 68.8121.97 ± 92.59
SecondaryPercentage of Participants With Any Adverse Event

An adverse event (AE) is defined as any untoward medical occurrence in a study participant and which does not necessarily have to have a causal relationship to treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the study treatment or protocol-specified procedure, whether or not considered related to study treatment or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study treatment is also an AE. The percentage of participants with any AE was assessed.

Time frame:
Up to 98 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Any Adverse Event
Percentage of participantsDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Percentage of Participants With Any Adverse Event84.682.8
SecondaryPercentage of Participants With Any Serious Adverse Event

A serious adverse event is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants with any SAE was assessed.

Time frame:
Up to 98 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Any Serious Adverse Event
Percentage of participantsDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Percentage of Participants With Any Serious Adverse Event7.08.6
SecondaryPercentage of Participants With Any Drug-related Adverse Event

The investigator was to determine if an AE had a reasonable possibility of a relationship to the study drug. The percentage of participants with any drug-related AE was assessed.

Time frame:
Up to 98 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Any Drug-related Adverse Event
Percentage of participantsDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Percentage of Participants With Any Drug-related Adverse Event32.132.1
SecondaryPercentage of Participants With Any Drug-related Serious Adverse Event

The percentage of participants with any drug-related SAE was assessed.

Time frame:
Up to 98 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Any Drug-related Serious Adverse Event
Percentage of participantsDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Percentage of Participants With Any Drug-related Serious Adverse Event0.30.3
SecondaryPercentage of Participants Who Discontinued Study Treatment Due to an Adverse Event

The percentage of participants who discontinued study treatment due to an AE was assessed.

Time frame:
Up to 96 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event
Percentage of participantsDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event1.63.4
SecondaryPercentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 48

The percentage of participants in each arm achieving HIV-1 RNA levels \<40 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 48
Percentage of participantsDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 4883.379.1
Statistical analysis
  • Doravirine 100 mg vs Daurunavir 800 mg + Ritonavir 100 mg · Treatment difference: 4.169 · 95% CI -1.404 to 9.743Stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum.
SecondaryPercentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 96

The percentage of participants in each arm achieving HIV-1 RNA levels \<40 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 96
Percentage of participantsDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg
Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 9672.064.4
Statistical analysis
  • Doravirine 100 mg vs Daurunavir 800 mg + Ritonavir 100 mg · Treatment difference: 7.606 · 95% CI 0.980 to 14.232Stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum.

Adverse events

Collected over Up to Week 386. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Doravirine 100 mg3/385 (0.8%)45/383 (11.7%)264/383 (68.9%)
Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg3/384 (0.8%)49/383 (12.8%)247/383 (64.5%)
Most frequent serious events
Showing 10 of 120
Most frequent serious events
EventDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg
AppendicitisInfections and infestations2/3831/383
Post procedural infectionInfections and infestations0/3832/383
TuberculosisInfections and infestations0/3832/383
Femur fractureInjury, poisoning and procedural complications2/3830/383
Post procedural haemorrhageInjury, poisoning and procedural complications0/3832/383
Back painMusculoskeletal and connective tissue disorders0/3832/383
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/3832/383
Febrile neutropeniaBlood and lymphatic system disorders0/3831/383
NeutropeniaBlood and lymphatic system disorders0/3831/383
Myocardial infarctionCardiac disorders1/3830/383
Most frequent other events
Showing 10 of 19
Most frequent other events
EventDoravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg
DiarrhoeaGastrointestinal disorders72/383100/383
Upper respiratory tract infectionInfections and infestations64/38340/383
HeadacheNervous system disorders63/38359/383
NasopharyngitisInfections and infestations61/38361/383
NauseaGastrointestinal disorders52/38354/383
SyphilisInfections and infestations29/38339/383
FatigueGeneral disorders38/38328/383
CoughRespiratory, thoracic and mediastinal disorders38/38314/383
BronchitisInfections and infestations31/38337/383
Back painMusculoskeletal and connective tissue disorders37/38313/383

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Doravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mgTotal
Mean34.9 ± 10.735.7 ± 10.735.3 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Doravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mgTotal
Female6558123
Male320326646
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Doravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mgTotal
Hispanic or Latino9386179
Not Hispanic or Latino286291577
Unknown or Not Reported6713
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Doravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mgTotal
American Indian or Alaska Native336
Asian7714
Native Hawaiian or Other Pacific Islander123
Black or African American8789176
White281280561
More than one race628
Unknown or Not Reported011
Mean Cluster of Differentiation 4 (CD4+) T-cell Count
Mean Cluster of Differentiation 4 (CD4+) T-cell Count(Cells/mm^3)Doravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mgTotal
Mean432.6 ± 208.4411.9 ± 229.6422.2 ± 219.4
Plasma HIV-1 RNA
Plasma HIV-1 RNA(Copies/mL)Doravirine 100 mgDaurunavir 800 mg + Ritonavir 100 mgTotal
Median27073.0 (105 to 2776658)27357.0 (235 to 3272236)27073.0 (105 to 3272236)
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA; DRIVE-FORWARD trial group. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV. 2020 Jan;7(1):e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15. PubMed 31740348 ↗
  • Orkin C, Molina JM, Lombaard J, DeJesus E, Rodgers A, Kumar S, Martin E, Hanna G, Hwang C. Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. Clin Infect Dis. 2020 Mar 17;70(7):1344-1352. doi: 10.1093/cid/ciz424. Erratum In: Clin Infect Dis. 2020 Jan 2;70(2):360. doi: 10.1093/cid/ciz1094. PubMed 31121015 ↗
  • Thompson M, Orkin C, Molina JM, Sax P, Cahn P, Squires K, Xu X, Rodgers A, Kumar S, Teppler H, Martin E, Hanna G, Hwang C. Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis. Clin Infect Dis. 2020 Mar 17;70(7):1336-1343. doi: 10.1093/cid/ciz423. PubMed 31121013 ↗
  • Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25. PubMed 29592840 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2014 to primary completion in Sep 2016, 21 months.

Results were first posted in Oct 2018, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2014
First posted
Oct 27, 2014
StartActual
Dec 1, 2014
Primary completionActual
Sep 29, 2016
CompletionActual
Mar 6, 2023
Results first posted
Oct 23, 2018
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02275780
Responsible party
Sponsor
First posted
Oct 27, 2014
Start date
Dec 1, 2014
Primary completion
Sep 29, 2016
Completion
Mar 6, 2023
Results posted
Oct 23, 2018
Last update
Oct 1, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doravirine

Start the discussion